Journal of the Academy of Consultation-Liaison Psychiatry · 2026
Metoclopramide Use in Nausea and Vomiting of Pregnancy and Risk of Depressive Symptoms as an Adverse Drug Reaction in the Netherlands: A Disproportionality Analysis in a National Spontaneous Reporting Database.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Conijn Maartje, van Tuyl Miranda, van Puijenbroek Eugene P, Maas Veronique Y F
Аннотация
BACKGROUND: Metoclopramide is widely used for nausea and vomiting of pregnancy and hyperemesis gravidarum. While it is known to cause depressive symptoms as an adverse drug reaction, it is unclear if pregnancy increases this risk.
OBJECTIVE: To assess whether metoclopramide-induced depressive symptoms are more common in pregnant women compared to nonpregnant women. to assess whether metoclopramide-induced depressive symptoms are more common in pregnant women compared to nonpregnant women.
METHODS: A disproportionality analysis was performed using the national spontaneous adverse drug reaction reporting system of the Netherlands. All reports of adverse drug reactions associated with metoclopramide concerning women aged 15-50 years were included. Based on Medical Dictionary for Regulatory Activities-coded terms and case narratives, pregnancy status was determined. Cases were defined as reports on depressive symptoms. A case review was performed. Disproportionality in reporting between pregnant and nonpregnant women was evaluated using a reporting odds ratio with 95% confidence interval. For comparison, 2 other antiemetic drugs (ondansetron and meclozine with pyridoxine) were also assessed.
RESULTS: Reports of depressive symptoms associated with metoclopramide use were reported more often in pregnant women (21.1%) than in nonpregnant women (3.0%; reporting odds ratio 8.6; 95% confidence interval 3.2-23.2). In pregnancy-related cases, depressive symptoms were reported more often following metoclopramide exposure (21.1%) compared to exposure to other antiemetics (7.3%; reporting odds ratio 3.4; 95% confidence interval 1.2-9.3). In 33.3% of the pregnancy-related cases, suicidality tendency was reported. Depressive symptoms were often accompanied by other mood-related symptoms including anxiety, panic attacks, agitation, and restlessness.
CONCLUSIONS: Although a causal relationship cannot be established, metoclopramide exposure during pregnancy was associated with increased reporting of depressive symptoms compared to both nonpregnant women and exposure to other antiemetics during pregnancy. This may be explained by a combination of pregnancy-related factors and the pharmacological mechanism of metoclopramide. Given the frequent co-occurrence of suicidal tendency, awareness of this possible adverse drug reaction is crucial for early recognition and prompt intervention to prevent symptom progression and improve maternal safety.
OBJECTIVE: To assess whether metoclopramide-induced depressive symptoms are more common in pregnant women compared to nonpregnant women. to assess whether metoclopramide-induced depressive symptoms are more common in pregnant women compared to nonpregnant women.
METHODS: A disproportionality analysis was performed using the national spontaneous adverse drug reaction reporting system of the Netherlands. All reports of adverse drug reactions associated with metoclopramide concerning women aged 15-50 years were included. Based on Medical Dictionary for Regulatory Activities-coded terms and case narratives, pregnancy status was determined. Cases were defined as reports on depressive symptoms. A case review was performed. Disproportionality in reporting between pregnant and nonpregnant women was evaluated using a reporting odds ratio with 95% confidence interval. For comparison, 2 other antiemetic drugs (ondansetron and meclozine with pyridoxine) were also assessed.
RESULTS: Reports of depressive symptoms associated with metoclopramide use were reported more often in pregnant women (21.1%) than in nonpregnant women (3.0%; reporting odds ratio 8.6; 95% confidence interval 3.2-23.2). In pregnancy-related cases, depressive symptoms were reported more often following metoclopramide exposure (21.1%) compared to exposure to other antiemetics (7.3%; reporting odds ratio 3.4; 95% confidence interval 1.2-9.3). In 33.3% of the pregnancy-related cases, suicidality tendency was reported. Depressive symptoms were often accompanied by other mood-related symptoms including anxiety, panic attacks, agitation, and restlessness.
CONCLUSIONS: Although a causal relationship cannot be established, metoclopramide exposure during pregnancy was associated with increased reporting of depressive symptoms compared to both nonpregnant women and exposure to other antiemetics during pregnancy. This may be explained by a combination of pregnancy-related factors and the pharmacological mechanism of metoclopramide. Given the frequent co-occurrence of suicidal tendency, awareness of this possible adverse drug reaction is crucial for early recognition and prompt intervention to prevent symptom progression and improve maternal safety.